Table 3.
Parameters related to bone metabolism at the end of the 12-week treatment.
| Normal-control(n=12) | OVX-control(n=12) | Positive-control (n=12) | OJa1(n=12) | OJa2(n=12) | |
|---|---|---|---|---|---|
| Serum Ca (mg/dL) | 10.8±1.3 | 11.4±1.3 | 10.7±1.2 | 11.2±1.3 | 10.8±1.1 |
| Serum P (mg/dL) | 7.08±0.93b | 8.32±0.98a | 7.17±0.95b | 8.24±0.97a | 7.05±0.89b* |
| ALP (IU/L) | 151±20b | 211±24a | 157±18b | 192±23a | 142±18b* |
| Serum osteocalcin(ng/mL) | 6.3±0.8b | 9.4±1.2a | 6.5±0.8b | 8.8 ±1.3a | 6.8±0.9b* |
Note: Each value represents the mean ± SD (n = 12).
OVX-control: the OVX rats consumed 0.5% dextrin; Positive-control: the OVX rats consumed 150 ug conjugated equine estrogen/kg bw + 0.5% dextrin; OJa1: the OVX rats consumed the 0.5% extract of SCB, ACB, MAL, and BPV (1:1:1:1, based on weights); OJa2: the OVX rats consumed 0.5% extract of SCB, PLA, COL and LCM (1:1:1:1, based on weights); Normal-control: the sham rats consumed 0.5% dextrin.
*Significantly different among the groups at each time point by one-way ANOVA at P < 0.05.
a,bMeans with different letters were significantly different among the groups by Tukey test at P < 0.05..